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A genetic polymorphism for translocator protein 18 kDa affects
both in vitro and in vivo radioligand binding in human brain
to this putative biomarker of neuroinﬂammation
William C Kreisl1, Kimberly J Jenko1, Christina S Hines1, Chul Hyoung Lyoo1, Winston Corona2, Cheryl L Morse1, Sami S Zoghbi1,
Thomas Hyde3, Joel E Kleinman4, Victor W Pike1, Francis J McMahon2, Robert B Innis1 and the Biomarkers Consortium PET Radioligand
Project Team
Second-generation radioligands for translocator protein (TSPO), an inﬂammation marker, are confounded by the codominant
rs6971 polymorphism that affects binding afﬁnity. The resulting three groups are homozygous for high-afﬁnity state (HH),
homozygous for low-afﬁnity state (LL), or heterozygous (HL). We tested if in vitro binding to leukocytes distinguished TSPO
genotypes and if genotype could affect clinical studies using the TSPO radioligand [11C]PBR28. In vitro binding to leukocytes and
[11C]PBR28 brain imaging were performed in 27 human subjects with known TSPO genotype. Speciﬁc [3H]PBR28 binding was
measured in prefrontal cortex of 45 schizophrenia patients and 47 controls. Leukocyte binding to PBR28 predicted genotype in all
subjects. Brain uptake wasB40% higher in HH than HL subjects. Speciﬁc [3H]PBR28 binding in LL controls was negligible, while HH
controls hadB80% higher binding than HL controls. After excluding LL subjects, speciﬁc binding was 16% greater in schizophrenia
patients than controls. This difference was insigniﬁcant by itself (P¼ 0.085), but was signiﬁcant after correcting for TSPO genotype
(P¼ 0.011). Our results show that TSPO genotype inﬂuences PBR28 binding in vitro and in vivo. Correcting for this genotype
increased statistical power in our postmortem study and is recommended for in vivo positron emission tomography studies.
Journal of Cerebral Blood Flow & Metabolism (2013) 33, 53–58; doi:10.1038/jcbfm.2012.131; published online 12 September 2012
Keywords: neuroinﬂammation; PBR28; schizophrenia; translocator protein
INTRODUCTION
Translocator protein 18 kDa (TSPO) is a proposed biomarker for
neuroinﬂammation. Positron emission tomography (PET) can
measure the density of this biomarker using radioligands that
bind to TSPO.1 The prototypical radioligand [11C](R)-PK 11195 has
been used to detect increased TSPO density in diverse disorders
characterized by neuroinﬂammation, including Alzheimer’s
disease, stroke, multiple sclerosis, rheumatoid arthritis, and fronto-
temporal dementia.2–6 However, [11C](R)-PK 11195 has several
disadvantages, including low speciﬁc-to-nonspeciﬁc binding.7
These limitations prompted the development of radioligands
with greater speciﬁc signal, including [11C]PBR28, [18F]PBR06,
[11C]DAA1106, [11C]DPA713, [18F]PBR111, [18F]FEPPA, and [11C]
AC-5216.8–14
Unfortunately, quantiﬁcation of binding for all tested second-
generation TSPO radioligands is confounded by the expression of
two different forms of TSPO, coded by the rs6971 single-
nucleotide polymorphism (SNP).15 This SNP in exon 4 of the
TSPO gene causes a nonconservative alanine-to-threonine
substitution in position 147. Among persons of European ances-
try, the predominant form (alanine) has a prevalence of B70%
and high-afﬁnity binding; the polymorphism (threonine) has a
prevalence of B30% and low-afﬁnity binding. The prevalence of
three resulting combinations is: 49% for homozygous high-afﬁnity
(HH); 9% for homozygous low-afﬁnity (LL); and 42% for
heterozygotes (HL) (http://hapmap.ncbi.nlm.nih.gov/cgi-perl/snp_
details_phase3?name=rs6971&source=hapmap28_B36&tmpl=snp_
details_phase3).
The existence of these two forms of TSPO was ﬁrst suggested by
PET scans using [11C]PBR28, which has about 50-fold differential
afﬁnity in HH compared with LL subjects.7,16 Furthermore, we
now know that all second-generation TSPO radioligands
have differential afﬁnity, ranging from fourfold to 50-fold.17
A recent study by Mizrahi et al18 using [18F]FEPPA was the ﬁrst
to demonstrate the association of TSPO genotype and variability
in PET imaging. To decrease variability in our PET studies, we
routinely exclude LL subjects (about 9% of the population) based
on low-afﬁnity binding to peripheral leukocytes. Nevertheless, our
PET subjects are a mixture of HH and HL genotypes, which
adds variability to measurements. Furthermore, PET studies using
other second-generation radioligands include all three genotypes
(HH, HL, and LL).
The differential afﬁnity of TSPO confounds the clinical applica-
tion of TSPO radioligands because it adds variance to the
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measurements. However, the degree to which TSPO genotype
inﬂuences in vivo binding measured by PET is unknown. This study
sought to assess the utility of in vitro receptor binding to
distinguish these three groups (HH, LL, and HL) and to extrapolate
its impact on the sensitivity of future clinical PET studies. More
speciﬁcally, we sought to determine: (1) if TSPO genotype
correlates with in vitro PBR28 binding using peripheral leukocytes
and in vivo using brain PET imaging; (2) if differential afﬁnity exists
for PBR28 both in controls and in disease states (in this case,
schizophrenia); and (3) if correcting for genotype improves the
sensitivity of PBR28 to detect group differences in TSPO density
measured in postmortem brain from schizophrenia subjects and
healthy controls. Finally, we estimated the nondisplaceable uptake
of [11C]PBR28 to further characterize the potential clinical utility of
this radioligand. Since HH and HL subjects are expected to have
different contributions of speciﬁc binding, we used the measured
total brain binding with PET (in vivo study) and the speciﬁc
binding in postmortem brain tissue (in vitro study) to estimate
nondisplaceable uptake. Because LL subjects are excluded from
our PET scans, we used only HH and HL subjects for leukocyte
binding and PET imaging studies in live subjects. For the
postmortem study conducted to assess between-group differ-
ences, all three genotypes were included.
MATERIALS AND METHODS
This study was approved by the NIMH Combined Neurosciences
Institutional Review Board and all volunteers gave their informed consent
before inclusion in the study.
In Vitro Study
In Vitro Leukocyte Assay. Leukocytes (white blood cells) were collected
from 32 healthy volunteers (27 were used in the in vivo study) and 9
patients with Alzheimer’s disease. Leukocytes were isolated and homo-
genized as previously described.7
To determine whether subjects were high- or mixed-afﬁnity binders,
heterologous receptor binding assays were performed using the racemic
radioligand [3H]PK 11195 (3.2 GBq/mmol; Perkin-Elmer Life and Analytical
Sciences, Boston, MA, USA), with cold PBR28 as the displacer. In brief,
100mL [3H]PK 11195 (B0.9 nmol/L) was added to each assay tube,
followed by 100mL of 12 cold PBR28 concentrations (0.01 to 3,000 nmol/L),
50mmol/L HEPES (pH¼ 7.4) buffer (to determine total binding), or
10mmol/L PBR28 (to determine nonspeciﬁc binding). In all, 100mL
leukocyte homogenate suspension (20mg/mL protein) was added to
each tube and incubated for 30minutes in a shaking water bath at
231C. Samples were ﬁltered with a Brandel cell harvester (Gaithersburg,
MD, USA) through Whatman GF/A ﬁlter paper (pretreated with 0.5%
polyethyleneimine), followed by three washes of 1mL ice-cold 50mmol/L
HEPES buffer (pH¼ 7.4; 41C). Radioactivity was measured with liquid
scintillation counting for ﬁve minutes using 4mL of Ultima-Gold (Perkin-
Elmer, Chicago, IL, USA).
Data for heterologous binding assays were analyzed using nonlinear
regression curve-ﬁtting software provided by GraphPad Prism 5 (GraphPad
Software, San Diego, CA, USA). A mean KD of 4.7 nmol/L for [
3H]11195 was
used as the dissociation constant to calculate Ki.
7 One- and two-site ﬁtting
were compared to determine which equation ﬁts best. Two-site ﬁtting was
the preferred model when the P value for null hypothesis (the one-site
ﬁtting) was o0.05. The HH were identiﬁed as subjects whose equation ﬁt
best to one-site ﬁtting with a Kio1 nmol/L. HL were identiﬁed as subjects
whose data best ﬁt the two-site equation.
Genetic Analysis. Genomic DNA from 49 subjects was included to
genotype the SNP, rs6971, within the TSPO gene on chromosome
22q13.2. This technique integrates a polymerase chain reaction (PCR)-
based assay with laser scanning technology to excite ﬂuorescent dyes
present in the specially designed TaqMan probes (Applied Biosystems,-
Carlsbad, CA, USA). One probe perfectly matched to the common (G) allele
labeled with VIC, and the second probe matched to the variant (A) allele
labeled with 6-carboxyﬂuorescein (FAM). Genomic DNA was extracted
from blood using the AutoGen automated systems and AutoGenFlex STAR
Whole Blood Extraction kit, catalog # AGKT-WB-640 (Holliston, MA, USA).
In all, 6 mL of human genomic DNA, at 2.5 ng/mL, from each subject, was
applied to 48 wells of a 96-well PCR plate and allowed to dry at 501C for
B3 hours. A working master mix was prepared that contained: 0.25 mL of
TaqMan genotyping probe mix (40 ), 2.25mL of TaqMan Genotyping
Master Mix (Applied Biosystems), and 2.5mL of water. Ultimately, a total of
5mL of this mix was added to the dry DNA samples along with 10 mL of
mineral oil to avoid evaporation during PCR cycling. The context sequence
[VIC/FAM] was as follows:
CCCCTACCTGGCCTGGCTGGCCTTC[A/G]CGACCACACTCAACTACTGCGTATG
Among 11 control samples genotyped, 4 of 4A/A, 4 of 4G/A, and 3 of 3G/G
samples produced the expected genotypes.
Postmortem Brain Samples. Postmortem samples of dorsolateral prefron-
tal cortex (DLPFC) tissue from 45 patients with schizophrenia and 47
healthy controls were collected as previously described.19 Informed
consent was obtained from family members according to established
guidelines. Medical, psychiatric, and substance use history, smoking status,
and demographic information were collected by telephone interview with
next-of-kin within 1 week of donation (Supplementary Table 1).
For individuals with schizophrenia, each case was reviewed by two
board-certiﬁed psychiatrists to establish DSM-IV Axis I lifetime psychiatric
diagnoses, using psychiatric record reviews and/or family informant
interviews.19 Normal controls had no history of signiﬁcant psychological
problems or care, psychiatric admissions, lifetime history of substance
abuse or dependence, or acute substance intoxication. Toxicology testing
was conducted on every case to screen for ethanol and illicit drugs. For
individuals with schizophrenia, additional testing was performed by
National Medical Services (Willow Grove, PN, USA) to assess antipsychotic
medication use at the time of death. Whenever possible, use of
antipsychotic medications was culled from available medical records and
converted to CPZ (chlorpromazine) equivalent (CPZE) doses in milligrams.
Gray matter tissue from the crown of the middle frontal gyrus was
obtained from the coronal slab midway between the frontal pole and the
most anterior extent of the genu of the corpus callosum. Dorsolateral
prefrontal cortex corresponding to Brodmann’s areas 9 and 46 was
dissected on dry ice using a hand-held dental drill and immediately stored
at  801C.
All brain samples had been genotyped for multiple loci, including the
rs6971 SNP, using Human 1M duo v3 chip via standard procedures
(Illumina, San Diego, CA, USA).
In Vitro [3H]PBR28 Receptor Binding Assay. Tissue was homogenized in
buffer (20mmol/L HEPES, 5mmol/L MgCl2, 1mmol/L EDTA, pH 7.4) with a
Teﬂon pestle using a Glas-Col Homogenizing System and centrifuged at
25,000g for 25minutes at 41C. The pellet was resuspended, aliquotted, and
stored at  801C. Protein concentration was determined using the Micro
BCA Protein Assay Kit (Thermo-Scientiﬁc, Rockford, IL, USA).
To determine the speciﬁc binding of PBR28, a two-point binding assay
was performed in triplicate. In all, 100mL [3H]PBR28 (speciﬁc activity
2.3GBq/mmol; Amersham, UK) was added to each assay tube, followed by
100mL of buffer (to determine total binding), or 10mmol/L cold PBR28 (to
determine nonspeciﬁc binding). In all, 100mL DLPFC homogenate suspen-
sion (B20mg/mL) was added last to initiate the incubation. Speciﬁc binding
was calculated by subtracting nonspeciﬁc binding from total binding.
Positron Emission Tomography Imaging with [11C]PBR28
Twenty-seven healthy volunteers (45.7±17.9 years) underwent [11C]PBR28
PET imaging. Supplementary Table 2 shows demographic information for
each subject.
[11C]PBR28 was synthesized as described in Investigational New Drug
Application #76 441, a copy of which is available at: http://pdsp.med.
unc.edu/snidd/. At the time of injection, [11C]PBR28 had high radio-
chemical purity (499%) and high-speciﬁc activity (122±67GBq/mmol).
The injected dose of [11C]PBR28 was 658±62MBq.
The procedures for scan acquisition and image analysis are similar to
those previously described for [11C]PBR28;16 these are described in detail in
the Supplementary Material. Total distribution volume (VT, mL/cm
3) was
calculated for each brain region. We followed proposed consensus
nomenclature for reversibly binding radioligands,20 where VT is the sum
of both speciﬁc and nondisplaceable uptake, which equals the ratio of
radioligand concentration in the brain to that in arterial plasma at
equilibrium and is proportional to receptor density.
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Estimation of Nondisplaceable Uptake of [11C]PBR28
We used the postmortem results to estimate the relative expression of H
and L forms in HL subjects, and then used total uptake (VT) measured in HH
and HL subjects from the PET data to estimate speciﬁc (VS) and
nondisplaceable uptake (VND) using the following equations.
VT¼VSþVND ð1Þ
VS HLð Þ ¼ xVSðHHÞ ð2Þ
Where x was determined by dividing the speciﬁc binding of [3H]PBR28 in
postmortem tissue in HL subjects by that in HH subjects. By combining
equations (1 and 2), and assuming VND is uniform across subjects:
VT HHð Þ ¼VSðHHÞ þVND ð3Þ
VT HLð Þ ¼ xVSðHHÞ þVND ð4Þ
Using the measured values of VT from the PET data of HH and HL subjects,
we then solved for VND to estimate the nonspeciﬁc uptake of [
11C]PBR28.
Statistical Analysis
Statistical analysis was performed using SPSS Statistics 17.0. Differences in
speciﬁc binding of [3H]PBR28 (in vitro study) and distribution volume (VT) of
[11C]PBR28 (in vivo study) were compared between HH and HL groups by
independent sample t-tests, and among all three genotypes by one-way
analysis of variance (ANOVA). Differences in the speciﬁc binding of
[3H]PBR28 between schizophrenia patients and controls was compared
using factorial ANOVA with genotype as a ﬁxed factor. Associations
between [3H]PBR28 binding and demographic variables were evaluated
using Pearson correlation analysis. Observed P values from t-tests were
corrected for multiple comparisons using the false discovery rate,21 with P
value threshold for signiﬁcance adjusted to¼ (n/7) 0.05, where n is the
rank of the observed P value for each of the seven brain regions tested.
Effects of demographic variables were evaluated with factorial ANOVA.
Data are given as mean±s.d.
RESULTS
In Vitro Leukocyte Assay Results Predicted Translocator Protein
Genotype
To determine if the HH and HL genotypes of TSPO correlated with
in vitro PBR28 binding, leukocytes were collected from 32 healthy
volunteers and 9 patients with Alzheimer’s disease. In 19 of these
subjects, the displacement curve best ﬁt a one-site model,
suggesting that these subjects express TSPO with high afﬁnity
for PBR28 (HH; Figure 1). The average Ki for these subjects was
0.52±0.21 nmol/L. For the remaining 22 subjects, the displace-
ment curve best ﬁt a two-site model, suggesting that these
subjects expressed two variants of TSPO (HL), one with high
afﬁnity for PBR28 (Ki of 0.22±0.13 nmol/L) and one with low
afﬁnity for PBR28 (Ki of 24.0±17.5 nmol/L). All subjects were
genotyped for the Ala147Thr polymorphism, and one- and two-
site ﬁts correctly identiﬁed the genotype in all subjects. That is, all
22 subjects with a two-site ﬁt of binding to leukocytes were
heterozygous, and all of the 19 HH subjects with a one-site ﬁt
were homozygous, for the G-allele.
The Ala147Thr Polymorphism Reduced [11C]PBR28 Binding In Vivo
To determine if TSPO genotype correlated with in vivo PBR28
binding, 27 healthy volunteers from the in vitro study (9 HH and 18
HL) also underwent PET imaging with [11C]PBR28. The HH subjects
had B40% greater [11C]PBR28 binding than HL subjects in all
regions measured (Po0.02; Table 1). The greater brain uptake in
HH versus HL subjects was not due to differential peripheral
factors of metabolism or plasma protein binding of the
radioligand. Brain uptake was measured as VT, which corrected
for differences in metabolism by normalizing brain uptake to
exposure from only the parent radioligand, separated from
radiometabolites. Even though the modeling corrects for differ-
ences in the arterial input function, the time-activity curves for
parent radioligand were very similar for both HH and HL groups
(Supplementary Figure 1A). In contrast, the brain time-activity
curves were different, with HH subjects showing slower washout
than HL subjects (Supplementary Figure 1B). In addition, the
plasma-free fraction (fP) of [
11C]PBR28 was not statistically
different between the HH and HL groups (4.6% versus 3.8%,
P¼ 0.19, overall mean¼ 4.1±1.4%).
Translocator Protein Showed Differential Afﬁnity in Brain Tissue
from Both Control and Schizophrenia Subjects
To simulate the effect of genotype on a potential clinical PET study
of TSPO, we measured [3H]PBR28 binding in postmortem samples
of DLPFC from 45 patients with schizophrenia and 47 control
subjects, all with known TSPO genotype. Among the controls,
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Figure 1. Representative displacement by PBR28 of [3H]PK 11195
binding to leukocyte membranes. PBR28 showed a one-site
displacement in high-affinity state (HH) subjects (n¼ 17) but a
two-site displacement in heterozygous (HL) subjects (n¼ 17). One-
and two-site fitting was determined by GraphPad Prism 5.0 and was
performed without knowledge of genotype. Symbols represent
mean±s.d., which was sometimes smaller than the symbol itself.
Table 1. Total [11C]PBR28 binding (VT, mL/cm
3)
Region HH
(n¼ 9)
HL
(n¼ 18)
P
value
Adjusted P value
threshold (FDR
corrected)
Medial
temporal
cortex
4.6
(1.5)
3.0
(0.8)
0.001 0.007
Cingulate
cortex
4.5
(0.6)
3.0
(0.8)
0.003 0.014
Temporal
cortex
4.6
(1.5)
3.2
(0.9)
0.007 0.021
Whole brain 4.5
(1.4)
3.2
(0.9)
0.008 0.029
Frontal
cortex
4.5
(1.4)
3.3
(0.9)
0.008 0.036
Parietal
cortex
4.4
(1.3)
3.3
(0.9)
0.014 0.043
Occipital
cortex
4.5
(1.4)
3.3
(0.9)
0.018 0.050
HH, high-affinity binder; HL, mixed-affinity binder; FDR, false discovery rate.
Data are given as mean with s.d. below in parenthesis.
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speciﬁc binding was higher in HH subjects (1,047±237 fmol/mg)
than HL (582±101 fmol/mg) and LL subjects (111±38 fmol/mg)
(Po0.001; Figure 2A). Although LL subjects had completely
separate speciﬁc binding values, HH and HL subjects had
overlapping values, showing that binding was affected by factors
other than genotype. Speciﬁc binding in HL controls was, on
average, 56% of that in HH controls. Individuals with schizo-
phrenia had a similar distribution of binding among the three
genotypes (Figure 2A). Speciﬁc binding was greater in HH patients
(1,303±426 fmol/mg) than in HL (664±121 fmol/mg) and LL
patients (91±95 fmol/mg, Po0.001). No interaction was noted
between speciﬁc [3H]PBR28 binding and age at death, gender,
race, height, weight, or body mass index.
Notably, HH schizophrenia patients had greater speciﬁc
[3H]PBR28 binding than HH controls (Figure 2A; P¼ 0.007);
however, HL schizophrenia patients did not have signiﬁcantly
higher binding than HL controls (P¼ 0.060), suggesting a blunted
association between schizophrenia and TSPO density in the HL
subjects. Moreover, when HH and HL subjects were grouped
together, brain tissue from individuals with schizophrenia showed
16% greater speciﬁc binding of [3H]PBR28 than brain tissue from
healthy controls (Figure 2B). By itself, this difference was initially
not statistically signiﬁcant (P¼ 0.085). However, when binding
afﬁnity status was included as a covariate in the statistical model,
this difference reached signiﬁcance (P¼ 0.011).
Schizophrenia patients were older at age of death (55.3±14.0
versus 41.6±13.7 years), which could explain the difference in
[3H]PBR28 binding between patient and controls. A signiﬁcant
correlation was noted in HH schizophrenia patients between
[3H]PBR28 binding and age of death (r¼ 0.44, P¼ 0.023);
however, no correlation was seen in HH controls or in HL subjects
of either group. In addition, a stronger correlation was seen
between [3H]PBR28 binding and duration of illness among HH
patients (r¼ 0.54, P¼ 0.006), suggesting that age at death is a
confounding factor related to the length of the course of
schizophrenia.
Because the difference in [3H]PBR28 binding could also be
explained by premortem antipsychotic medication use in schizo-
phrenia patients, we investigated the possible association
between [3H]PBR28 binding and antipsychotic use. We found
that speciﬁc binding was the same in schizophrenia patients
taking antipsychotics at the time of death (1,028±445 fmol/mg,
n¼ 34) as those not taking antipsychotics (1,136±545 fmol/mg,
n¼ 9), even after correcting for TSPO genotype (P¼ 0.687).
Speciﬁc [3H]PBR28 binding did not correlate with median, lifetime,
or last CPZE dose in HH or HL patients (P40.21). When the
statistical model included TSPO genotype and antipsychotic
medication use as covariates, schizophrenia patients still had
signiﬁcantly greater speciﬁc [3H]PBR28 binding (P¼ 0.015).
Schizophrenia patients had lower measures of brain pH
(6.2±0.2 versus 6.5±0.3), shorter brain storage time before
analysis (8.1±2.8 versus 10.1±3.2 years), and greater prevalence
of premortem nicotine use (79.1% versus 31.0%) than controls
(Supplementary Table 1); however, neither brain pH nor brain
storage time signiﬁcantly correlated with speciﬁc [3H]PBR28
binding in either controls or schizophrenia patients (P40.1). In
addition, nicotine users did not have different speciﬁc binding
than nonusers (P¼ 0.312, LL subjects excluded).
Estimation of Nondisplaceable Uptake of [11C]PBR28
We used the postmortem results to estimate the relative
expression of H and L forms in HL subjects, and then used total
uptake (VT) in HH and HL subjects to estimate speciﬁc (VS) and
nondisplaceable uptake (VND).
VT¼VSþVND ð1Þ
We assumed that binding to the L form is negligible (2%)
compared with that to the H form and that VND is uniform across
all subjects. The postmortem study showed that speciﬁc binding
in HL subjects was 56% of that in HH subjects (Figure 2).
VS HLð Þ ¼ 0:56VSðHHÞ ð2Þ
VT for whole brain in HH subjects, as measured by PET, was 1.4
times that in HL subjects (Table 1).
VTðHHÞ ¼ 4:5mL/cm3¼VSðHHÞ þVND ð3Þ
VTðHLÞ ¼ 3:2mL/cm3¼ 0:56VSðHHÞ þVND ð4Þ
The solution of all four equations predicts that VND¼ 1.6mL/cm3.
DISCUSSION
The results of this study demonstrate that both in vitro and in vivo
binding of PBR28 correlated with the Ala147Thr polymorphism in
the TSPO gene. In vitro displacement assays with peripheral
leukocytes accurately predicted TSPO genotype in all subjects.
Thus, it appears that either leukocyte binding or genotyping can
be used to accurately separate TSPO genotypes. In vivo, brain
uptake of [11C]PBR28 was on average 40% higher in HH than in HL
subjects, but with signiﬁcant overlap. In addition, TSPO binding in
postmortem brain from individuals with schizophrenia was 16%
higher than in control brain, an effect that was statistically
signiﬁcant only after correcting for TSPO genotype. Our results
strongly suggest that clinical studies with [11C]PBR28 will have
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Figure 2. Specific [3H]PBR28 binding in dorsolateral prefrontal cortex (DLPFC) from schizophrenia patients (SZ) and healthy controls (HC) with
(A) and without (B) stratification based on genotype. (A) Using a one-way analysis of variance (ANOVA), specific binding in the high-affinity
state (HH) group was statistically significant as follows: *Po0.001 versus heterozygous (HL) and low-affinity state (LL) SZ, and P¼ 0.007 versus
HH HC. **Po0.001 versus HL and LL HC, wPo0.001 versus LL HC. (B) The distribution of specific binding for HH and HL subjects shown in this
panel would mimic positron emission tomography (PET) imaging results in living patients, after our typical exclusion of LL subjects. One-way
ANOVA resulted in nonsignificant differences between HC and SZ groups (P¼ 0.085). When genotype was added to the statistical model as a
fixed factor; however, SZ patients had significantly greater specific binding than HC subjects (P¼ 0.011).
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increased statistical power and require smaller sample sizes if they
incorporate the genotype of the subjects. Thus, we recommend
measuring the Ala147Thr polymorphism in all future studies
using [11C]PBR28, as well as in other second-generation TSPO
radioligands.
The results of this study are particularly important because they
demonstrate that the Ala147Thr polymorphism is associated with
reduced binding afﬁnity to PBR28 in vitro as well as total
radioligand binding in vivo. This indicates that PET data from
clinical studies using [11C]PBR28 are inﬂuenced by the presence or
absence of this TSPO polymorphism, underscoring the importance
of determining genotype in studies using this radioligand. Based
on our results, displacement binding assay results are equivalent
to those from genotype analysis using PCR, allowing ﬂexibility for
investigators interested in using [11C]PBR28.
It is important to note that although we have treated this
Ala147Thr polymorphism as a nuisance variable that adds noise to
PET imaging, it might also have clinical signiﬁcance. Translocator
protein in the outer mitochondrial membrane transports choles-
terol to CYP11A1 on the inner mitochondrial membrane to
synthesize pregnenolone, a precursor for steroids. Thus, increased
expression of TSPO in macrophages and activated microglia
appear critical for the increased production of steroids by these
inﬂammatory cells. We are aware of only one prior study on the
effect of this Ala147Thr polymorphism on steroid production, in
which Costa et al22 found that Thr147 homozygous or
heterozygous volunteers had less pregnenolone in peripheral
lymphocytes than Ala147 homozygous volunteers. Therefore, it is
possible that HL and LL individuals have a reduced ability to
respond to host cell injury via TSPO-mediated pathways.
Translocator Protein Binding in Schizophrenia
The ﬁnding that schizophrenic brain has greater speciﬁc binding
of [3H]PBR28 than control brain was not a working hypothesis of
this study; however, this result is consistent with the hypothesis
that inﬂammatory processes are associated with schizophrenia.
These results are particularly important given conﬂicting results
seen in prior studies on schizophrenia. While some studies
reported no signiﬁcant differences in microglial cell density or
TSPO binding sites between patients with schizophrenia and
controls,23–25 others found elevated microglial density in DLPFC,
temporal gyrus, temporal cortex, and frontal cortex of
schizophrenia patients.26–28 Still others reported decreased
microglical activation or TSPO speciﬁc binding in schizophrenia
patients compared with controls.29,30 A study using [11C](R)-PK
11195 found a 16% increase in total gray matter binding in
schizophrenia patients;31 however, all 10 patients included were
taking antipsychotic medication and the effect of antipsychotics
on microglial activation is unknown. In our study, speciﬁc
[3H]PBR28 binding was not greater in schizophrenic DLPFC
taking antipsychotics at time of death than in those not taking
antipsychotics, when differences in TSPO genotype were taken
into account. Moreover, speciﬁc binding was greater for
schizophrenia patients than controls even after accounting for
antipsychotic use in the statistical model. While we cannot
conclude deﬁnitively that antipsychotic use does not inﬂuence
TSPO density, the results from our study show no evidence of such
an association.
Using Genotype with Other Translocator Protein Radioligands
While this study was speciﬁc to PBR28, all other second-
generation TSPO radioligands examined to date have differential
afﬁnity for the target protein.17 Thus, the Ala147Thr polymorphism
may confound results using any of these second-generation TSPO
radioligands by increasing variance or by the differential inclusion
of the three genotypes in experimental and control groups. In fact,
a recent report demonstrated that TSPO genotype was associated
with differences in brain uptake of [18F]FEPPA in human
subjects.18 Therefore, we recommend genotyping subjects
before prospective clinical studies using any second-generation
TSPO radioligands. Furthermore, the original and prototypical
ligand [11C](R)-PK 11195 may also have differential afﬁnity,
with conﬂicting results reported using in vitro32 and in vivo7
methods. Thus, additional in vitro and in vivo studies are necessary
to determine the utility of genotype in studies using [11C](R)-PK
11195.
One of the most important attributes of a PET radioligand is its
ratio of speciﬁc to nondisplaceable brain uptake, the latter of
which is the sum of nonspeciﬁc binding and free radioligand in
tissue water. For targets like TSPO, which are widely distributed in
brain, nondisplaceable uptake of the cognate radioligand can only
be measured after pharmacological blockade by nonradioactive
ligand. Such blockade is often impossible to perform in humans
because the drug is not available or because of pharmacological
effects. Our postmortem and in vivo results provide a relatively
unique opportunity to estimate nondisplaceable uptake without
pharmacological blockade. We used the postmortem results to
estimate the relative expression of H and L forms in HL subjects,
and then used total uptake (VT) in HH and HL subjects to estimate
speciﬁc (VS) and nondisplaceable uptake (VND).
Our estimation of VND yielded two interesting results. First, the
postmortem study showed that speciﬁc binding in HL subjects
was 56% (and not 50%) of that in HH subjects (Figure 2). These
results suggest that 56% of TSPO in heterozygotes is in the H form,
not the 50% that would be expected if HL subjects were to
express the H and L versions of the TSPO gene in equal amounts.
Such a disparity could occur by differential expression of the two
genes or differential turnover of two TSPO proteins. Second, our
calculations predict that VND of [
11C]PBR28 is 1.6mL/cm3. Thus, the
ratio of speciﬁc to nondisplaceable uptake of [11C]PBR28 in HH
subjects is 1.8/1 (¼ (4.5–1.6)/1.6). This estimated value of VND and
VND/fP in human subjects (1.6 and 39.0mL/cm
3, respectively) is
very similar to that measured in monkey brain (1.6 and 28.6mL/
cm3, respectively) after pharmacological blockade.33 Although
speciﬁc binding often differs between species, nonspeciﬁc binding
(after correcting for plasma protein binding) is often thought to be
similar across species, because of the similar chemical composition
of brain tissue.
These calculations show that in vitro binding and in vivo brain
uptake in a situation of altered receptor binding (i.e., affected by
genotype) can be used to calculate nondisplaceable uptake in
human brain. Similar measurements could be made for other TSPO
radioligands to compare their relative ratios of speciﬁc to
nondisplaceable uptake. This method is preferred over simply
using VT of LL subjects as an estimation of VND. Prior studies using
[11C]PBR28 have shown that kinetic modeling using either the one-
and two-tissue compartment models provides poor ﬁtting with
measured brain PET data in LL subjects.16 Therefore, VT of LL
subjects cannot be accurately calculated using kinetic modeling
and cannot be used to estimate VND of [
11C]PBR28. Our method of
calculating VND is admittedly speculative and requires the
assumption that (1) VND is uniform among subjects, (2) the ratio
of speciﬁc binding between HH and HL subjects is the same in vitro
and in vivo, and (3) speciﬁc binding of PBR28 to the L version of
TSPO is negligible. However, these are reasonable assumptions
given (1) the similar chemical composition of brain tissue among
human subjects, (2) TSPO density is not expected to change
disproportionately between HH and HL subjects postmortem, and
(3) results from our postmortem study show dramatically lower
speciﬁc binding in LL subjects than HH subjects.
In conclusion, the Ala147Thr TSPO polymorphism was asso-
ciated with reduced in vivo binding with [11C]PBR28. The leukocyte
binding assay accurately predicted the Ala147Thr polymorphism
and may be used as an alternative to genotyping. Controlling
for this polymorphism will not only provide more accurate
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quantitation of TSPO density but also increase statistical power
and reduce the necessary sample size of clinical studies using
[11C]PBR28. Patients with schizophrenia had greater TSPO binding
in DLPFC. Whether this truly reﬂects a neuroinﬂammatory process
in schizophrenia is unknown, but could be explored with TSPO
PET imaging in live subjects after correcting for the Ala147Thr
polymorphism.
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